These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31119966)

  • 1. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate.
    Foss FM; Parker TL; Girardi M; Li A
    Leuk Lymphoma; 2019 Dec; 60(12):2927-2930. PubMed ID: 31119966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy.
    Koch E; Story SK; Geskin LJ
    Leuk Lymphoma; 2013 Nov; 54(11):2448-51. PubMed ID: 23442065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pralatrexate (Folotyn).
    Abramovits W; Oquendo M; Granowski P; Gupta A; Cather J
    Skinmed; 2012; 10(4):244-6. PubMed ID: 23008944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    Jennifer C Z; Sara Mohamed J; Salma A; Francine F
    Expert Rev Hematol; 2020 Jun; 13(6):577-583. PubMed ID: 32293930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
    Horwitz SM; Kim YH; Foss F; Zain JM; Myskowski PL; Lechowicz MJ; Fisher DC; Shustov AR; Bartlett NL; Delioukina ML; Koutsoukos T; Saunders ME; O'Connor OA; Duvic M
    Blood; 2012 May; 119(18):4115-22. PubMed ID: 22394596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.
    Duvic M; Kim YH; Zinzani PL; Horwitz SM
    Clin Cancer Res; 2017 Jul; 23(14):3552-3556. PubMed ID: 28167509
    [No Abstract]   [Full Text] [Related]  

  • 7. Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.
    Hong JY; Yoon DH; Yoon SE; Kim SJ; Lee HS; Eom HS; Lee HW; Shin DY; Koh Y; Yoon SS; Jo JC; Kim JS; Kim SJ; Cho SH; Lee WS; Won JH; Kim WS; Suh C
    Sci Rep; 2019 Dec; 9(1):20302. PubMed ID: 31889144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate.
    Foss FM; Parker TL; Girardi M; Li A
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e445-e447. PubMed ID: 30181105
    [No Abstract]   [Full Text] [Related]  

  • 9. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
    O'Connor OA; Pro B; Pinter-Brown L; Bartlett N; Popplewell L; Coiffier B; Lechowicz MJ; Savage KJ; Shustov AR; Gisselbrecht C; Jacobsen E; Zinzani PL; Furman R; Goy A; Haioun C; Crump M; Zain JM; Hsi E; Boyd A; Horwitz S
    J Clin Oncol; 2011 Mar; 29(9):1182-9. PubMed ID: 21245435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind.
    Altınay S; Kural A; Özmen A; Tural D; Tutar Y
    Anticancer Agents Med Chem; 2023; 23(3):298-305. PubMed ID: 35692151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.
    Lee SS; Jung SH; Ahn JS; Kim YK; Cho MS; Jung SY; Lee JJ; Kim HJ; Yang DH
    J Korean Med Sci; 2016 Jul; 31(7):1160-3. PubMed ID: 27366017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
    Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pralatrexate experience in PTCL: A multicenter retrospective study from Turkey.
    Sinan Dal M; Merdin A; Erkurt MA; Ekinci Ö; Albayrak M; Kabukcu Hacıoglu S; Kaya A; Dogu MH; Hindilerden F; Sarici A; Merter M; Reis Aras M; Akgun Caglıyan G; Kizil Cakar M; Aydogdu I; Kuku I; Korkmaz S; Ulas T; Eser B; Altuntas F
    J BUON; 2021; 26(4):1536-1539. PubMed ID: 34565016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.
    Maruyama D; Nagai H; Maeda Y; Nakane T; Shimoyama T; Nakazato T; Sakai R; Ishikawa T; Izutsu K; Ueda R; Tobinai K
    Cancer Sci; 2017 Oct; 108(10):2061-2068. PubMed ID: 28771889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
    Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
    Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.
    Foss FM
    Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1141-52. PubMed ID: 21726160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Leucovorin Administration Allows Continued Pralatrexate Treatment in a Patient with Angioimmunoblastic T-Cell Lymphoma].
    Sawada K; Sata H; Yasumi M; Karasuno T
    Gan To Kagaku Ryoho; 2020 Jan; 47(1):95-97. PubMed ID: 32381871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
    Hui J; Przespo E; Elefante A
    J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.
    Dondi A; Bari A; Pozzi S; Ferri P; Sacchi S
    Expert Opin Investig Drugs; 2014 May; 23(5):711-8. PubMed ID: 24661228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.
    Hong X; Song Y; Huang H; Bai B; Zhang H; Ke X; Shi Y; Zhu J; Lu G; Liebscher S; Cai C
    Target Oncol; 2019 Apr; 14(2):149-158. PubMed ID: 30904980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.